肿瘤细胞治疗研究
英文原题：TCR engineered T cells for solid tumor immunotherapy.
T 细胞免疫治疗仍是肿瘤免疫治疗中颇具吸引力的一种方法。
T 细胞免疫疗法仍是癌症免疫治疗中有吸引力的方法，主要采用嵌合抗原受体（CAR）和 T 细胞受体（TCR）工程化 T 细胞。CAR-T 细胞疗法是治疗血液系统恶性肿瘤的重要突破。TCR-T 细胞能够识别表达于细胞表面和细胞内区室的抗原。虽然 TCR-T 尚未获批临床应用，但已开展多项临床试验，尤其针对实体瘤。本文总结 TCR-T 细胞的当前进展及其在实体瘤免疫治疗中的潜在优势。
T cell immunotherapy remains an attractive approach for cancer immunotherapy. T cell immunotherapy mainly employs chimeric antigen receptor (CAR)- and T cell receptor (TCR)-engineered T cells. CAR-T cell therapy has been an essential breakthrough in treating hematological malignancies. TCR-T cells can recognize antigens expressed both on cell surfaces and in intracellular compartments. Although TCR-T cells have not been approved for clinical application, a number of clinical trials have been performed, particularly for solid tumors. In this article, we summarized current TCR-T cell advances and their potential advantages for solid tumor immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
